• Skip to primary navigation
  • Skip to content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Business Directory
    • Buyers | Licensees
    • Sellers | Ancillary Businesses
    • Submit Product & Service Press Release
  • CBE Exchange
  • CBE Jobs Exchange
  • Events
  • Featured Videos
  • Product & Service Press Releases
  • Sponsored Polls
  • Webinars
    • Upcoming Webinars
    • Archived Webinars
  • Whitepapers

Cannabis Business Executive - Cannabis and Marijuana industry news

Recreational, Medical, Marijuana, Cannabis, And Hemp News for Cannabis Businesses

  • Follow on Facebook
  • Follow on Twitter
  • Follow on Google+
  • Follow on LinkedIn
  • Subscribe to our RSS feed
Newsletter 2
  • Home
  • Policy & Legal
    • Hemp Business Executive
    • International
      • Canada
      • Mexico
      • Israel
    • US A to F
      • Alabama
      • Alaska
      • Arizona
      • Arkansas
      • California
      • Colorado
      • Connecticut
      • Delaware
      • District of Columbia
      • Florida
    • US G to M
      • Georgia
      • Hawaii
      • Illinois
      • Indiana
      • Idaho
      • Iowa
      • Kansas
      • Kentucky
      • Louisiana
      • Maine
      • Maryland
      • Massachusetts
    • US M to N
      • Michigan
      • Minnesota
      • Mississippi
      • Missouri
      • Montana
      • Nebraska
      • Nevada
      • New Hampshire
      • New Jersey
      • New Mexico
      • New York
      • North Carolina
      • North Dakota
    • US O to V
      • Ohio
      • Oklahoma
      • Oregon
      • Pennsylvania
      • Rhode Island
      • South Carolina
      • South Dakota
      • Tennessee
      • Texas
      • Utah
      • Vermont
    • US V to W
      • Virginia
      • Washington
      • Wisconsin
      • Wyoming
      • Guam
      • Puerto Rico
  • Industry News
    • Advertising, Marketing, PR & Research
    • Banking, Finance & Real Estate
    • Compliance and Regulations
    • Corporate Social Responsibility
    • Retailers
    • Hemp Business Executive
    • HR and Staffing
    • North Of The Border
    • Industry People/On the Move
    • Packaging and Supplies
    • Press Releases
    • Processors
    • Producers
    • Security Solutions
    • Science and Technology
    • South Of The Border
  • CBE Lists
    • Ancillary Businesses
      • 2019 CBE Ancillary Business Survey CLICK HERE
      • 2018 CBE 155 A/B
      • 2017 CBE 150 A/B
      • 2016 CBE 100 A/B
    • Producers, Processors, Retailers
      • 2017 CBE 200 PPRs
      • 2015 CBE 100 PPRs
    • Industry Women
      • Glass Ceiling Wreckers: 2019 CBE Power Women of Cannabis
      • 2017 CBE 75 Most Important Women
      • 2016 CBE Top 50 Women
      • 2014 CBE Most Influential Women
    • Most Important Companies
      • 2016 CBE 10 Most Important Companies
      • 2014 CBE 10 Most Important Companies
    • Political 100
      • 2017 CBE Political 100
      • 2016 CBE 100 Political
      • 2014 CBE Political 50
    • 2014 CBE 100 Most Important People
    • CBE RFP Hotlists
      • 2014 CBE Lab Testing Services HotList
      • 2016 BHO Extraction Equipment
      • 2016 CBE Supercritical CO2 Extraction Equipment
      • 2016 CBE Security Solutions
      • 2016 Edibles & Infused Products
  • Company Stories
    • Up and Comers
  • Hemp Business Executive
    • Hemp Policy & Legal
    • Hemp Industry News
    • Hemp State Regulatory Agencies
  • Newsletters
    • CBE Week
    • CBE Human Capital Management
    • CBE Technology & Solutions
    • CBE Policy and Legal Update
    • CBE Product and Service Announcements
  • Op-Ed
    • Cartoons
    • The Buck Stops Here
    • Opinions
    • Comments
  • Associations
  • State Regulatory Agencies
    • Marijuana
    • Hemp
  • Contact
  • AB Survey
  • About Us
  • Account
  • Accounting Services
  • Advertise
  • Advertising, PR & Marketing
  • All Cannabis News
  • Ancillary Business Survey 2018
  • Ancillary Business Survey 2019
  • Archived Webinars
  • Associations & Organizations
  • Banking & Payment Processing
  • Better Start for the Glass Ceiling in this Industry, CBE’s Most Influential Women
  • Book Reviews
  • Business Directory
  • Business Directory Introduction
  • Business Directory Listing
  • Business Directory Manage
  • Business Directory Registration Info
  • Business Directory Welcome
  • Call for speakers
  • Cannabis Investments
  • Cart
  • CBE Exchange
  • CBE HotLists
    • CBE Lab Testing Services HotList 2014
  • CBE Lists
  • CBE Political 50
  • CBE Press LLC Privacy Statement
  • CBE Press News
  • Checkout
  • Consulting Services
  • Consumption Gear
  • Contact
  • Contribute
  • Contributors
  • Create Your Product & Service Press Release
  • Creative Submission
  • Cultivation Products & Services
  • Current Poll
  • Edible & Infused Products
  • Editor’s Page
  • Email Whitelisting Instructions
  • Event Listing Questionaire
  • Featured Videos
  • Funding Options
  • Hemp State Regulatory List
  • Home
  • Human Capital Management Newsletters
  • Industry Jobs
  • Join the CBE Business Directory
  • Join the Directory
  • Lab Testing Regulations
  • Lab Testing Services
  • Login
  • Logout
  • Marijuana State Regulatory Contacts
  • Marijuana Tax Facts
  • Media Kit
  • Medical Marijuana Qualifying Conditions
  • Members
  • MJ Media Kit
  • Most Popular Stories
  • Most Read Stories
  • New Product & Service Listings Welcome
  • News Releases
  • Newsletters
    • Ask CBE
    • CBE Human Capital Management
    • CBE Policy and Legal Update
    • CBE Product and Service Announcements
    • CBE Technology & Solutions
    • CBE Week
  • On the Move
  • Organizations & Associations
  • Packaging & Supplies
  • Password Reset
  • Policy & Legal
  • PPR Survey
  • Product Releases
  • Profile Update
  • Register
  • Security Solutions
  • Software & Technology
  • Sponsored Polls
  • State Cannabis Product Packaging Requirements
  • Terms of Service
  • Thank You
  • The Most Influential People in the Cannabis Industry, The Cannabis Business Executive 100
  • Training & Educational Services
  • Upcoming Webinars
  • User
  • Whitepapers
  • WV Senate passes medical marijuana bill to House
  • Categories
  • Locations
  • My Bookings
You are here: Home / Hemp Business Executive / Hemp Policy & Legal / FDA’s Draft Guidance for Clinical Research Regarding Cannabis and Cannabis Derivatives Takes a Firm Stance on the 0.3% THC Level

FDA’s Draft Guidance for Clinical Research Regarding Cannabis and Cannabis Derivatives Takes a Firm Stance on the 0.3% THC Level

August 25, 2020 by Agustin Rodriguez Leave a Comment

 By Agustin Rodriguez and Dascher Pasco 

On Tuesday, July 21, 2020, the U.S. Food and Drug Administration (FDA) issued “Cannabis and Cannabis-Derived Compounds: Quality Considerations for Clinical Research, Draft Guidance for Industry.” This is the first draft guidance from the FDA regarding the cannabis industry, and while nothing stated was surprising to those within the industry, it does provide insight into FDA’s current thinking on clinical research in the course of the development of drugs containing cannabis or cannabis-derived compounds. The draft guidance covers topics such as sources of cannabis for clinical research, information on quality considerations and recommendations regarding calculating delta-9 tetrahydrocannabinol (THC) levels. The draft guidance also introduces key FDA regulatory concepts to stakeholders who may be less familiar with the FDA and the FDA’s authorities.

The FDA’s draft guidance begins with a review of the effects of the 2018 Farm Bill, which decriminalized hemp, defined as cannabis with a concentration of THC at or below 0.3 percent on a dry weight basis. Accordingly, hemp is now legal at the federal level and subject to the control of the United States Department of Agriculture (USDA) and FDA. Marijuana, defined as cannabis with more than 0.3 percent THC, remains federally illegal and is subject to the Controlled Substances Act (CSA) and the authority of the Drug Enforcement Administration (DEA) and other criminal law enforcement agencies.

With that background in mind, the draft guidance makes it clear that research on cannabis will be held to the same baseline regulatory standards as research on any other botanical raw material, drug substance or drug product. Accordingly, existing FDA guidance governing those issues should be consulted. While cannabis is held to the same regulatory standards as other botanical products in many respects, the draft guidance does emphasize certain distinctions. First, it identifies specific principles and documents for pursuing drug development using cannabis or cannabis-derived compounds. These resources emphasize the need for consistency among products, safety considerations and other requirements governing botanical materials as well as drugs and devices.[1]Second, it emphasizes that published studies should not be relied upon in place of a full toxicological program. This requirement highlights the FDA’s desire to ensure a thorough understanding of the effects of cannabis in all contexts. Third, it calls out distinctions in research requirements for hemp and marijuana.

The FDA’s draft guidance notes that, for many years, cannabis could only be sourced from the National Institute on Drug Abuse (NIDA) Drug Supply Program (DSP), but as a result of the removal of hemp from the CSA, researchers can source hemp from cultivators who produce their product pursuant to a state, tribal, or other USDA approved plan. As for marijuana, NIDA DSP remains the only domestic federally legal source of cannabis over the 0.3 percent THC limit for clinical research; however, the DEA is in the process of allowing additional growers to register with the agency to produce and distribute cannabis for research purposes.

This is not the first federal guidance that highlights the DEA’s continued role in the regulation of cannabis due to the continued illegality of marijuana. The USDA’s interim final rule required that hemp growers have their product tested by a DEA-registered lab and that non-compliant plants were to be disposed of through a DEA-registered reverse distributor or law enforcement. While the USDA delayed these requirements, they were not abandoned, and this FDA draft guidance reinforces that the DEA will continue to play a key role in the regulation of the cannabis industry to ensure that hemp products do not exceed the 0.3 percent THC concentration threshold.

Further highlighting the FDA’s emphasis on the importance of the 0.3 percent THC concentration limit is the draft guidance’s relatively detailed discussion of what constitutes hemp. The FDA states unequivocally that activities related to growing and manufacturing cannabis for use as an investigational drug for research must comply with CSA and DEA requirements. The draft guidance requires that THC levels be tested at each phase of development during the research process, highlighting concerns about THC levels not only in raw forms of cannabis (i.e. hemp and marijuana plants), but in all forms of cannabis-derived products. This includes, for example, where a manufacturing process generates materials, such as intermediates or accumulated by-products, that exceed the 0.3 percent THC threshold even if the source material or finished product does not exceed the threshold.

The practical result of this requirement is that cannabis and cannabis derivatives must maintain a THC level at or below 0.3 percent at all times, and with no identified margin of error. This can be difficult to ensure because THC levels are susceptible to outside influences, some of which may be beyond growers, researchers, or manufacturers’ control. It also answers in the negative a question that some have been asking: is a product that contains THC in excess of 0.3 percent, that itself comes from extracts derived from legal hemp, still lawful? Section 297A of the 2018 Farm Bill defines “hemp” as “the plant Cannabis sativa L. and any part of that plant, including the seeds thereof and all derivatives, extracts, cannabinoids, isomers, acids, salts, and salts of isomers, whether growing or not,with a delta-9 tetrahydrocannabinol concentration of not more than 0.3 percent on a dry weight basis” (emphasis added). The language of the definition appears to require hemp derivatives to also maintain a THC level at or below 0.3 percent.

Given the demand for cannabis and cannabis derivatives is growing, the FDA’s focus on the level of THC at every step of the research process will not comfort investors or researchers. Because researchers are required to test THC levels in their products throughout the research process, there is a higher likelihood that they will run across a “hot” product incident.  Researchers encountering levels of THC above the 0.3 percent threshold are encouraged by FDA to contact the DEA in advance. The suggestion to contact DEA rather than to immediately dispose of the product in a manner consistent with the guidance found in the USDA interim rule suggests that DEA may be willing to negotiate certain process controls and “hot” product incidents may not result in the immediate destruction of the product.

Short of that, the draft guidance requirement for testing of cannabis and cannabis-derivatives throughout the research process drives more cost into supply chains and study controls because it requires researchers to strictly control for THC in product at all points along the research protocol. This must be done both to avoid contamination of their data and to avoid potential criminal liability. As a result, investors are forced to contend with both a higher price tag on the research and the threat of the destruction of the product.

Assuming implementation of this draft guidance, researchers should ensure they conduct appropriate due diligence when sourcing their materials. This includes reviewing growers’ licenses and testing results to make sure all raw cannabis materials are compliant with USDA requirements. Furthermore, given the suggestion that DEA may be willing to negotiate certain controls, appropriate protocols should be in place to contact DEA in the event a products tests above the 0.3 percent level.

Ultimately, FDA’s draft guidance does not necessarily provide comfort for researchers and investors hoping to reduce the risk of investing behind research in cannabis and cannabis-derivatives. Nevertheless, additional clarity into FDA’s expectations, even if incremental, helps industry put in place testing and due diligence to mitigate that risk. The draft guidance comment period is open until September 21, 2020. It is likely that, as with the USDA interim rule, we will see industry comments pushing back on the strict THC threshold level that leaves so little room for error in the cannabis supply chain.

About The Co-Author

Dascher Pasco is a member of the firm’s Government and Regulatory group. She earned her Juris Doctor from the University of Virginia School of Law where she served as the president of Virginia Law Women and the Jewish Law Student Association, and an editor of the Virginia Journal of International Law.

After law school, Dascher clerked for the Honorable Norman K. Moon of the United States District Court for the Western District of Virginia.

____________________________________________________________________________

[1]Specifically, FDA identifies a number of chapters found in the United States Pharmacopeia and the National Formulary governing tests, equipment, analytical methods for drug quality aspects such as identification, excipients, impurities, and microbiological controls for sterile as well as nonsterile products. FDA also highlights a number of rules and regulations regarding drugs and devices including those governing container closure systems.

Filed Under: Hemp Policy & Legal Tagged With: clinical research, Draft Guidance, Drug Enforcement Agency (DEA), U.S. Food and Drug Administration (FDA)

About Agustin Rodriguez

With over two decades of experience in-house and in private practice, Agustin Rodriquez provides cross-functional, multidisciplinary counsel to advertising, marketing and consumer goods and services companies. He brings years of experience managing in-house legal teams for a Fortune 200 international consumer packaged goods company, handling complex litigation, marketing, advertising, tobacco, cannabis and alcohol regulations and restrictions, international supply chain risk management, internal investigations and corporate compliance, transactions and governance.

Primary Sidebar

Ad: Sidebar 1

Featured Video

Associations & Organizations

clearing div

Ad: Sidebar 2

Business Directory

Ad: Skyscraper 1

CBE Jobs Exchange


Featured Jobs
Go
Post a Job
More jobs
Powered by CBEJobsExchange.com

RSS Recent Jobs

  • Business Development Officer - Specialty Ag - Bank Michigan - Ann Arbor, MI
  • Field Applications Support Scientist - Danaher - Framingham, MA
  • Flash Chromatography Applications Chemist - VRS Recruitment - , NY

Product & Service Press Releases

Ad: Sidebar 3

CBE Events

Ad: Sidebar 4

State Regulatory Agencies

Ad: Skyscraper 2

Webinars

Ad: Sidebar 5

Associations & Organizations

Ad: Sidebar 6

Featured Video

Ad: Skyscraper 3

Business Directory

Ad: Sidebar 7

CBE Jobs Exchange

Ad: Sidebar 8

CBE Events

Ad: Skyscraper 4

Industry Blogs



Footer

  • Home
  • About Us
  • Advertise
  • Contact
  • CBE Press LLC Privacy Statement
  • Contribute
  • Contributors
  • Newsletters
  • Terms of Service
  • Contributor Login
  • Follow on Facebook
  • Follow on Twitter
  • Follow on Google+
  • Follow on LinkedIn
  • Subscribe to our RSS feed
Newsletter 2

© Copyright 2020 CBE PRESS LLC. - All Rights Reserved. Cannabis Business Executive Is A Trademark Of CBE PRESS LLC. · All Rights Reserved · And Our Sitemap · All Logos & Trademarks Belong To Their Respective Owners·